A bundled intervention to support patients with opioid use disorder after emergency department discharge
A Bundled Intervention to End Opioid Overdose by Increasing Treatment Uptake Post Emergency Department Discharge
This study tests a new support program for people with opioid use disorder who have recently been treated for an overdose to see if it helps them get better care and reduces the chances of another overdose.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 190 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT06593093 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to address the high rates of opioid overdose deaths among patients discharged from emergency departments by implementing a bundled intervention. The approach includes telehealth services, peer support specialists, and the prescription of buprenorphine, along with connections to ongoing addiction care. The study will evaluate the effectiveness of this intervention in increasing treatment uptake and reducing repeat overdoses in patients with opioid use disorder who have experienced an overdose in the past year. By targeting barriers to treatment, the trial seeks to improve outcomes for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 19 and older who have a diagnosis of opioid use disorder and have experienced an opioid overdose in the last 12 months.
Not a fit: Patients living in restricted environments, those currently enrolled in other clinical studies, or those with severe medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly reduce opioid overdose deaths and improve treatment adherence among patients with opioid use disorder.
How similar studies have performed: While similar interventions using telehealth and peer support have shown promise in improving treatment uptake, this specific bundled approach remains novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. discharged from the ED and inpatient settings at the UAB hospital 2. 19 years or older (the age of majority in Alabama); 3. diagnosis of OUD and experiencing opioid overdose in the last 12 months; 4. prescribed buprenorphine in the ED and willing to continue buprenorphine post-ED discharge; 5. English speaking; 6. not actively psychotic and suicidal, or cognitively impaired. 7. Patients who are admitted to the hospital from the ED will be eligible for enrollment. Exclusion Criteria: 1. living in a restricted environment (e.g., prison or jail facility, etc.); 2. currently enrolled in other clinical studies; 3. anticipated to take other prescribed opioids except buprenorphine for a medical condition longer than three months; 4. known allergic reaction to buprenorphine; 5. critically ill or injured; 6. females with pregnancy (they are anticipated to request a higher level of care). 7. living outside of Alabama
Where this trial is running
Birmingham, Alabama
- UAB — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Principal investigator: Li Li, MD;PhD — University of Alabama at Birmingham
- Study coordinator: Li Li, MD;PhD
- Email: liyli@uabmc.edu
- Phone: 2059346269
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.